Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

A report covers extended follow-up of an in vivo BCMA CAR-T therapy for relapsed/refractory multiple myeloma. No further context was provided beyond the headline, so the specific findings and conclusions of this follow-up cannot be confirmed from the available information.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.